Shim Joong Sup, Liu Jun O
1. Faculty of Health Sciences, University of Macau, Av. Padre Tomas Pereira, Taipa, Macau SAR, China.
2. Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, 725 N Wolfe St, Baltimore, MD 21205, USA.
Int J Biol Sci. 2014 Jun 10;10(7):654-63. doi: 10.7150/ijbs.9224. eCollection 2014.
Drug repositioning (also referred to as drug repurposing), the process of finding new uses of existing drugs, has been gaining popularity in recent years. The availability of several established clinical drug libraries and rapid advances in disease biology, genomics and bioinformatics has accelerated the pace of both activity-based and in silico drug repositioning. Drug repositioning has attracted particular attention from the communities engaged in anticancer drug discovery due to the combination of great demand for new anticancer drugs and the availability of a wide variety of cell- and target-based screening assays. With the successful clinical introduction of a number of non-cancer drugs for cancer treatment, drug repositioning now became a powerful alternative strategy to discover and develop novel anticancer drug candidates from the existing drug space. In this review, recent successful examples of drug repositioning for anticancer drug discovery from non-cancer drugs will be discussed.
药物重新定位(也称为药物再利用),即寻找现有药物新用途的过程,近年来越来越受欢迎。多个已建立的临床药物库的可用性以及疾病生物学、基因组学和生物信息学的快速发展,加快了基于活性和计算机辅助药物重新定位的步伐。由于对新型抗癌药物的巨大需求以及各种基于细胞和靶点的筛选试验的可用性,药物重新定位引起了从事抗癌药物发现的群体的特别关注。随着多种非癌症药物成功用于癌症治疗的临床应用,药物重新定位现已成为从现有药物领域发现和开发新型抗癌药物候选物的有力替代策略。在本综述中,将讨论最近从非癌症药物中发现抗癌药物的药物重新定位成功案例。